Project Grant R37CA296577
Award Date
6/1/25
Completion Date
5/31/30
Dollars Obligated
$483K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This is a Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) to the Sanford Burnham Prebys Medical Discovery Institute. The $2,397,277 award, with a performance period from September 2024 to August 2029, supports research to investigate the mechanisms by which metabolic stress and mitochondrial dysfunction contribute to the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC), the most common type of primary...
This $163,319 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), supports research to understand how disruption of the circadian clock contributes to the development and progression of colorectal cancer (CRC), particularly in younger populations. The University of California, Irvine is the primary awardee and will conduct this research over a period of approximately 1 year starting September 2024. The research aims to elucidate...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research into the central mechanisms underlying disruptions to the circadian rhythm of glucocorticoids (e.g., cortisol) in breast cancer patients. The $456,048 award to Cold Spring Harbor Laboratory aims to systematically determine where along the hypothalamic-pituitary-adrenal (HPA) axis the dysfunction occurs, identify the driving mechanisms, and then utilize approaches to manipulate...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to decipher the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a highly lethal form of liver cancer. The $518,219 award, effective from April 4, 2025 to March 31, 2030, will support research at the University of Pittsburgh to investigate how the activation of the FXR and CAR nuclear receptors in the context of cholestatic liver diseases, such as primary...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $451,250 to support research investigating the molecular mechanisms that coordinate circadian clock gene expression in the brain's central pacemaker and peripheral oscillators. The 5-year project aims to elucidate how internal and external signals, particularly light exposure, are integrated to regulate circadian...
This $361,454 federal Project Grant award was issued by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859). The grant supports research to elucidate the molecular mechanisms underlying circadian clock period compensation in fungi and mammals. The key objectives are to: 1) Define cellular effectors and metabolic variables controlling circadian oscillations in fungi, and test for conservation in human cells, and 2)...
This $447,944 Project Grant was awarded on July 17, 2024 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to Baylor College of Medicine in Houston, Texas. The grant supports scientific research aimed at understanding the fundamental biological mechanisms underlying hepatoblastoma (HB), the most common liver tumor in children. The key goals are to: 1) Assess differences in NRF2 activity among primary HB tumors, circulating tumor cells (CTCs), and lung metastases, comparing...
The National Cancer Institute (NCI) awarded a $483,591 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, Davis (UC Davis) with an effective date of August 1, 2024 and a planned completion by July 31, 2029. The grant supports research to design, clone, express, and purify novel "bioengineered RNA" (bioRNA) molecules that can target and modulate the metabolism of hepatocellular carcinoma (HCC), the most common form of liver cancer....
The National Cancer Institute (NCI) has awarded a 5-year, $599,299 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the University of Illinois in Chicago. The goal of this research project is to further validate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and its impact on the development of non-alcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC). The researchers will employ a mouse model of NASH-induced HCC to study how HK2 regulates...
This $146,816 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research training and investigation into the role of the muscle circadian clock as a modifier of cancer cachexia. The key objectives are to: 1) Define the stage of cancer cachexia at which the muscle clock is disrupted and examine the relationship between clock disruption...